Skip to main content
Français National
Donate Now
Safety and efficacy of SGLT-2 inhibitors in patients with advanced CKD

Lay Abstract Sodium-glucose co-transporter-2 (SGLT-2) inhibitors were introduced in medical practice for the treatment of type 2 diabetes. Subsequently, they were found to protect against adverse cardiac events and progression of chronic kidney disease (CKD) to more advance...

The effects of SGLT2 inhibition on renal PGE2 mediated transport in diabetes

Lay Abstract We have worked with several diabetic models (8-10, 12) and have the materials and technical expertise to carry out the proposed biochemical, functional, and translational studies at the Kidney Research Centre. Considering the timeline needed to conduct these lo...

The efficacy, mechanisms and safety of SGLT2i and GLP1RA combination therapy in kidney transplant re

Lay Abstract Kidney transplant recipients (KTR) are at high risk of death from heart disease after transplantation, as well as graft failure, where the kidney transplant no longer works and dialysis or another kidney transplant is required.  New types of drugs called sodium...

Kidney Community Kitchen

Diet plays a significant role in the management of chronic kidney disease to prevent the build-up of toxins that healthy kidneys normally remove and to reduce the workload of the kidneys. Proper food and fluid choices can contribute to delaying the need for dialysis treatment...

Deciphering the inflammatory proprieties of crystalloids: Why Saline is bad?

General Audience Summary Inflammation is present in all intensive care patients. Leukocytes, white blood cells are important in the inflammatory response. However, when the inflammation is too great, the compensatory mechanisms of the patients are overwhelmed and the pati...

Expanding the Use of SGLT-2 Inhibitors to Improve Cardiorenal Disease

Lay Abstract Background Sodium glucose co-transporter 2 (SGLT-2) inhibitors are a class of medication that alter blood flow in the kidney, thereby reducing the risks of developing heart failure and/ or kidney failure by up to 40%. These medications have been principally stu...

Team Grant : Diabetes Mechanisms

CIHR Team Grant: Diabetes Mechanisms and Translational solutions The Kidney Foundation has partnered with the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes to support the Team Grant: Diabetes Mechanisms and Translational solutions ....

The use of new glucose lowering therapies to reduce cardiorenal risk in kidney transplant recipients

Supervisor(s):  David Cherney Lay Abstract Background: Approximately 4 million Canadians live with chronic kidney disease, a progressive condition which worsens over time leading to kidney failure. Individuals with kidney failure suffer from disability, depression, incr...

Treatment Modalities for Kidney Failure

In the early stages of chronic kidney disease, lifestyle changes (such as getting more exercise, stopping smoking and cutting down on sodium), managing other medical conditions and taking a few medications may be all the treatment needed to slow the damage to the kidneys. Peo...

Colleagues celebrate Dr. Chan’s Medal for Research Excellence

Elizabeth Myles, National Executive Director at The Kidney Foundation of Canada, and Dr. John Chan, Chief of the Laboratory of Molecular Endocrinology and Nephrology at the Research Centre of the Centre Hospitalier de l'Université de Montréal (CHUM) and Professor of Medicine...

|<  <   1 2 3    >  >| Pages: 2 of 3